Literature DB >> 19901119

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Lisa R Treviño1, Noriko Shimasaki, Wenjian Yang, John C Panetta, Cheng Cheng, Deqing Pei, Diana Chan, Alex Sparreboom, Kathleen M Giacomini, Ching-Hon Pui, William E Evans, Mary V Relling.   

Abstract

PURPOSE: Methotrexate plasma concentration is related to its clinical effects. Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: We performed a genome-wide analysis of 500,568 germline single-nucleotide polymorphisms (SNPs) to identify how inheritance affects methotrexate plasma disposition among 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m(2). SNPs were validated in an independent cohort of 206 patients.
RESULTS: Adjusting for age, race, sex, and methotrexate regimen, the most significant associations were with SNPs in the organic anion transporter polypeptide, SLCO1B1. Two SNPs in SLCO1B1, rs11045879 (P = 1.7 x 10(-10)) and rs4149081 (P = 1.7 x 10(-9)), were in linkage disequilibrium (LD) with each other (r(2) = 1) and with a functional polymorphism in SLCO1B1, T521C (rs4149056; r(2) > 0.84). rs11045879 and rs4149081 were validated in an independent cohort of 206 patients (P = .018 and P = .017), as were other SLCO1B1 SNPs residing in different LD blocks. SNPs in SLCO1B1 were also associated with GI toxicity (odds ratio, 15.3 to 16.4; P = .03 to .004).
CONCLUSION: A genome-wide interrogation identified inherited variations in a plausible, yet heretofore low-priority candidate gene, SLCO1B1, as important determinants of methotrexate's pharmacokinetics and clinical effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901119      PMCID: PMC2793040          DOI: 10.1200/JCO.2008.20.4156

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  57 in total

Review 1.  Pharmacogenetics and adverse drug reactions.

Authors:  U A Meyer
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

2.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.

Authors:  Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon T Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel Gudbjartsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Andrew D Morris; Charlotte H Kimber; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Wing-Yee So; Peter C Y Tong; Maggie C Y Ng; Torben Hansen; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Alejandro Tres; Fernando Fuertes; Manuel Ruiz-Echarri; Laura Asin; Berta Saez; Erica van Boven; Siem Klaver; Dorine W Swinkels; Katja K Aben; Theresa Graif; John Cashy; Brian K Suarez; Onco van Vierssen Trip; Michael L Frigge; Carole Ober; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Colin N A Palmer; Charles Rotimi; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Rafn Benediktsson; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; William J Catalona; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

Review 3.  Role of OATP transporters in the disposition of drugs.

Authors:  Mikko Niemi
Journal:  Pharmacogenomics       Date:  2007-07       Impact factor: 2.533

4.  High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.

Authors:  Norman Jaffe; Richard Gorlick
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

5.  Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.

Authors:  Caroline Laverdière; Sonia Chiasson; Irina Costea; Albert Moghrabi; Maja Krajinovic
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

6.  Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Authors:  R G Tirona; B F Leake; G Merino; R B Kim
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

7.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.

Authors:  T Abe; M Unno; T Onogawa; T Tokui; T N Kondo; R Nakagomi; H Adachi; K Fujiwara; M Okabe; T Suzuki; K Nunoki; E Sato; M Kakyo; T Nishio; J Sugita; N Asano; M Tanemoto; M Seki; F Date; K Ono; Y Kondo; K Shiiba; M Suzuki; H Ohtani; T Shimosegawa; K Iinuma; H Nagura; S Ito; S Matsuno
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

8.  Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Authors:  M K Pasanen; H Fredrikson; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2007-05-02       Impact factor: 6.875

9.  Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Authors:  Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

10.  Genomewide association analysis of coronary artery disease.

Authors:  Nilesh J Samani; Jeanette Erdmann; Alistair S Hall; Christian Hengstenberg; Massimo Mangino; Bjoern Mayer; Richard J Dixon; Thomas Meitinger; Peter Braund; H-Erich Wichmann; Jennifer H Barrett; Inke R König; Suzanne E Stevens; Silke Szymczak; David-Alexandre Tregouet; Mark M Iles; Friedrich Pahlke; Helen Pollard; Wolfgang Lieb; Francois Cambien; Marcus Fischer; Willem Ouwehand; Stefan Blankenberg; Anthony J Balmforth; Andrea Baessler; Stephen G Ball; Tim M Strom; Ingrid Braenne; Christian Gieger; Panos Deloukas; Martin D Tobin; Andreas Ziegler; John R Thompson; Heribert Schunkert
Journal:  N Engl J Med       Date:  2007-07-18       Impact factor: 91.245

View more
  118 in total

1.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Authors:  Laura B Ramsey; Gitte H Bruun; Wenjian Yang; Lisa R Treviño; Selina Vattathil; Paul Scheet; Cheng Cheng; Gary L Rosner; Kathleen M Giacomini; Yiping Fan; Alex Sparreboom; Torben S Mikkelsen; Thomas J Corydon; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Genome Res       Date:  2011-12-06       Impact factor: 9.043

Review 2.  Genome-wide association studies in pharmacogenomics.

Authors:  Ann K Daly
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 3.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

4.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 5.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-27       Impact factor: 4.481

Review 6.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

7.  Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

8.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.

Authors:  Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2013-05       Impact factor: 2.089

10.  PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.

Authors:  Gabriele Stocco; Wenjian Yang; Kristine R Crews; William E Thierfelder; Giuliana Decorti; Margherita Londero; Raffaella Franca; Marco Rabusin; Maria Grazia Valsecchi; Deqing Pei; Cheng Cheng; Steven W Paugh; Laura B Ramsey; Barthelemy Diouf; Joseph Robert McCorkle; Terreia S Jones; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Hum Mol Genet       Date:  2012-07-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.